The relationship between body composition and left ventricular performance in women with breast, lymphoma, or sarcoma cancer.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardio-oncology Pub Date : 2024-06-06 DOI:10.1186/s40959-024-00233-1
Leila Mabudian, Kerry Reding, Ralph B D'Agostino, Emily M Heiston, Moriah P Bellissimo, Kristine Olson, William O Ntim, Heidi D Klepin, Emily V Dressler, Tonya Moore, Jennifer H Jordan, Nathaniel S O'Connell, Amy Ladd, Kathryn E Weaver, Bonnie Ky, Lynne I Wagner, Mary Helen Hackney, Glenn J Lesser, W Gregory Hundley
{"title":"The relationship between body composition and left ventricular performance in women with breast, lymphoma, or sarcoma cancer.","authors":"Leila Mabudian, Kerry Reding, Ralph B D'Agostino, Emily M Heiston, Moriah P Bellissimo, Kristine Olson, William O Ntim, Heidi D Klepin, Emily V Dressler, Tonya Moore, Jennifer H Jordan, Nathaniel S O'Connell, Amy Ladd, Kathryn E Weaver, Bonnie Ky, Lynne I Wagner, Mary Helen Hackney, Glenn J Lesser, W Gregory Hundley","doi":"10.1186/s40959-024-00233-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To understand how body composition in those with elevated body mass index impacts left ventricular function decline during cancer treatment, we determined the association between baseline body mass index (BMI), intra-abdominal adipose tissue (IAT) and subcutaneous adipose tissue (SAT) with baseline to 3-month left ventricular ejection fraction (LVEF) change among women receiving potentially cardiotoxic chemotherapy for breast cancer, lymphoma, or sarcoma.</p><p><strong>Methods: </strong>Women underwent potentially cardiotoxic chemotherapy, such as doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab, for treatment of breast cancer, lymphoma, or sarcoma. We obtained magnetic resonance images (MRIs) of body composition and cardiac function prior to treatment, and then a repeat MRI for cardiac function assessment at three months into treatment. Analyses and assessment of abdominal adipose tissue volumes and LVEF outcomes were conducted by independent reviewers blinded to all patient identifiers. A general linear model was created to examine associations between adipose tissue depots, BMI, and 3-month LVEF change.</p><p><strong>Results: </strong>Women (n = 210) aged 56 ± 11 years with breast cancer, lymphoma, and sarcoma were enrolled (n = 195, 14, 1 respectively). Baseline BMI, IAT, and SAT fat were independently associated with 3-month LVEF declines (p = 0.001 to 0.025 for all). After adjusting for baseline cardiovascular disease risk factors, BMI, IAT, and SAT, BMI remained the only variable associated with 3-month LVEF decline (p = 0.047).</p><p><strong>Conclusions: </strong>These results suggest that factors other than abdominal adipose tissue or traditional cardiovascular risk factors may contribute to 3-month declines in LVEF among women with elevated BMI receiving potentially cardiotoxic chemotherapy. Further investigation should be conducted on psychosocial stress, physical activity, sleep, or diet.</p><p><strong>Trial registration: </strong>DETECTIV_NCT01719562, WF99112, & WF97415-NCT02791581.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11155055/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardio-oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40959-024-00233-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: To understand how body composition in those with elevated body mass index impacts left ventricular function decline during cancer treatment, we determined the association between baseline body mass index (BMI), intra-abdominal adipose tissue (IAT) and subcutaneous adipose tissue (SAT) with baseline to 3-month left ventricular ejection fraction (LVEF) change among women receiving potentially cardiotoxic chemotherapy for breast cancer, lymphoma, or sarcoma.

Methods: Women underwent potentially cardiotoxic chemotherapy, such as doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab, for treatment of breast cancer, lymphoma, or sarcoma. We obtained magnetic resonance images (MRIs) of body composition and cardiac function prior to treatment, and then a repeat MRI for cardiac function assessment at three months into treatment. Analyses and assessment of abdominal adipose tissue volumes and LVEF outcomes were conducted by independent reviewers blinded to all patient identifiers. A general linear model was created to examine associations between adipose tissue depots, BMI, and 3-month LVEF change.

Results: Women (n = 210) aged 56 ± 11 years with breast cancer, lymphoma, and sarcoma were enrolled (n = 195, 14, 1 respectively). Baseline BMI, IAT, and SAT fat were independently associated with 3-month LVEF declines (p = 0.001 to 0.025 for all). After adjusting for baseline cardiovascular disease risk factors, BMI, IAT, and SAT, BMI remained the only variable associated with 3-month LVEF decline (p = 0.047).

Conclusions: These results suggest that factors other than abdominal adipose tissue or traditional cardiovascular risk factors may contribute to 3-month declines in LVEF among women with elevated BMI receiving potentially cardiotoxic chemotherapy. Further investigation should be conducted on psychosocial stress, physical activity, sleep, or diet.

Trial registration: DETECTIV_NCT01719562, WF99112, & WF97415-NCT02791581.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺癌、淋巴瘤或肉瘤女性患者的身体成分与左心室功能之间的关系。
背景:为了了解体质指数升高者的身体成分如何影响癌症治疗期间左心室功能的下降,我们测定了因乳腺癌、淋巴瘤或肉瘤接受潜在心脏毒性化疗的妇女的基线体质指数(BMI)、腹腔内脂肪组织(IAT)和皮下脂肪组织(SAT)与基线至3个月左心室射血分数(LVEF)变化之间的关系:接受多柔比星、环磷酰胺、紫杉醇和曲妥珠单抗等潜在心脏毒性化疗以治疗乳腺癌、淋巴瘤或肉瘤的女性。我们在治疗前获得了身体成分和心脏功能的磁共振成像(MRI),并在治疗三个月后再次进行磁共振成像以评估心脏功能。腹部脂肪组织体积和 LVEF 结果的分析和评估由独立审查员进行,他们对所有患者的身份识别信息都是盲法。建立了一个一般线性模型来研究脂肪组织沉积、体重指数和 3 个月 LVEF 变化之间的关联:年龄在 56 ± 11 岁之间、患有乳腺癌、淋巴瘤和肉瘤的女性(n = 210)(分别为 195、14、1 人)被纳入研究。基线体重指数、IAT和SAT脂肪与3个月的LVEF下降有独立关联(所有指标的p = 0.001至0.025)。在对基线心血管疾病风险因素、BMI、IAT和SAT进行调整后,BMI仍然是唯一与3个月LVEF下降相关的变量(p = 0.047):这些结果表明,除了腹部脂肪组织或传统的心血管风险因素外,其他因素也可能导致接受潜在心脏毒性化疗的 BMI 升高妇女的 LVEF 在 3 个月内下降。应进一步调查社会心理压力、体育锻炼、睡眠或饮食等因素:试验注册:DECTIV_NCT01719562、WF99112 和 WF97415-NCT02791581。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardio-oncology
Cardio-oncology Medicine-Cardiology and Cardiovascular Medicine
CiteScore
5.00
自引率
3.00%
发文量
17
审稿时长
7 weeks
期刊最新文献
Enhancing nurse competence in early recognition of cardiotoxicity. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: an updated systematic review and meta-analysis. Routine Ankle-Brachial Index (ABI) measurement: a window into atherosclerosis and early left ventricular dysfunction in patients diagnosed with cancer. Cardiovascular and venous thromboembolism risks in cancer patients treated with immune checkpoint inhibitors compared to non-users- a multi-center retrospective study. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - PILOT trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1